Merck Press Releases

Published on June 30, 2014 - 10:31 GMT

Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK- …

Distribution channels: Companies

Published on June 30, 2014 - 10:19 GMT

Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK- …

Distribution channels: Companies

Published on June 24, 2014 - 13:49 GMT

FDA Accepts Merck’s NDA for Fixed-Dose Combination of Raltegravir with Lamivudine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for a fixed-dose combination (FDC) of raltegravir with lamivudine for the treatment of HIV-1 infection (MK-0518B) has been accepted …

Distribution channels: Companies

Published on June 23, 2014 - 21:53 GMT

Merck to Hold Second-Quarter 2014 Sales and Earnings Conference Call on July 29

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July …

Distribution channels: Companies

Published on June 23, 2014 - 12:20 GMT

Merck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the future appointment of Michael J. Holston as general counsel, effective July 01, 2015. Holston, who will also oversee …

Distribution channels: Companies

Published on June 20, 2014 - 12:16 GMT

Merck Begins Tender Offer to Acquire Idenix

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc …

Distribution channels: Companies

Published on June 14, 2014 - 17:13 GMT

New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with …

Distribution channels: Companies

Published on June 14, 2014 - 17:13 GMT

Late-Breaking Observational Data Show Patients with Type 2 Diabetes Taking JANUVIA® (sitagliptin) and Metformin Initiated Insulin ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating …

Distribution channels: Companies

Published on June 13, 2014 - 13:14 GMT

Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of a global registry to evaluate the experiences and outcomes of approximately 20,000 patients with type 2 diabetes …

Distribution channels: Companies

Published on June 9, 2014 - 12:38 GMT

Merck to Acquire Idenix

WHITEHOUSE STATION, N.J. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the companies have entered into a definitive agreement …

Distribution channels: Companies

Published on June 6, 2014 - 12:49 GMT

First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir)

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once- …

Distribution channels: Companies

Published on June 6, 2014 - 12:49 GMT

Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA® (sitagliptin) and for its investigational once-weekly …

Distribution channels: Companies

Published on June 6, 2014 - 12:39 GMT

First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir)

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once- …

Distribution channels: Companies

Published on June 2, 2014 - 12:20 GMT

First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, ...

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD-1 antibody, as initial therapy in patients …

Distribution channels: Companies

Published on June 2, 2014 - 12:20 GMT

Data on Merck’s Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ...

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from the company’s large ongoing Phase 1b study (KEYNOTE-001) evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD-1 …

Distribution channels: Companies

Published on June 1, 2014 - 13:37 GMT

First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and ...

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of early findings from a Phase 1b study (KEYNOTE-012) evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD- …

Distribution channels: Companies

Published on May 27, 2014 - 16:54 GMT

Merck Announces Third-Quarter 2014 Dividend

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the company’s common stock for the third …

Distribution channels: Companies

Published on May 19, 2014 - 21:28 GMT

Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging ...

WHITEHOUSE STATION, N.J. WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) …

Distribution channels: Companies

Published on May 14, 2014 - 14:00 GMT

The American College of Endocrinology & Merck Urge Patients with Type 2 Diabetes to Work with Their Doctor to Get to Their Blood ...

Today, the American College of Endocrinology (ACE), with support from Merck, known as MSD outside the United States and Canada, has launched the new Blood Sugar Basics: Get to Your Goals program to help educate the nearly 26 million Americans living with …

Distribution channels: Companies

Published on May 14, 2014 - 12:14 GMT

Merck’s Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data for the company’s investigational anti-PD-1 antibody, MK-3475, in advanced melanoma, non-small cell lung cancer ( …

Distribution channels: Companies

Merck Press Releases Distributed by EIN Presswire